The Dilemma of TP53 Codon 72 Polymorphism (rs1042522) and
Breast Cancer Risk: A Case-Control Study and Meta-Analysis
in The Iranian Population
The first three authors equally contributed to this work.
Afzaljavan F, Chaeichi Tehrani N, Rivandi M, Zarif Ghasemian S, Vahednia E, Khayami R, Abavisani M, Pasdar A. The dilemma of TP53 codon 72 polymorphism (rs1042522) and breast cancer risk: a case-control study and meta-analysis in the Iranian population. Cell J. 2020; 22(2): 185 192. doi: 10.22074/cellj.2020.6458.
Mutations of TP53 as a tumor suppressor gene are frequently observed in different types of cancer. A
codon 72 polymorphism located on exon 4 with two alleles encoding either Proline (CCC) or Arginine (CGC) has been
indicated as a common variation in association with cancers. Controversial results have been reported regarding the
association of allelic polymorphism of codon 72 of
Materials and Methods
In this case-control study, blood sample of 622 participants, including 308 breast cancer
cases and 314 controls were collected. Genotyping for rs1042522 was conducted by Allele Specific polymerase chain
reaction (AS-PCR). In order to set a meta-analysis study, PubMed, Scopus and ISI Web of Knowledge and Persian
databases were searched to explore relevant studies, published up to September 2018, containing information on
All retrieved available data as well as the results of our current study were consisted of 1965 breast cancer cases and 1999 healthy controls. No significant difference was observed in allele frequencies between groups (P=0.90) in our study. The cumulative results did not also show any association between rs1042522 and breast cancer risk on the dominant (P=0.61) and recessive (P=0.89) models.
These findings cannot support contribution of rs1042522 polymorphism to breast cancer risk in an Iranian population. Future larger studies may help confirm this finding with a greater power. .